Commentary
See article on page 88Heparin and inflammation: a new use for an old GAG?
| The first 150 words of the full text of this article appear below. |
Since its discovery in 1917, heparin has been a fascinating, and in a way elusive, molecule. Heparin is a glycosoaminoglycan (GAG) formed by repeated sulphated oligosaccharide units. Natural preparations of heparin (usually obtained from bovine lung or porcine intestinal mucosa) can vary in the length of the polymeric unit and therefore have different molecular weights. As such, the biological actions of this GAG can vary quantitatively between different batches of the molecule. The initial activity ascribed to heparin was its capacity to prolong the process of blood clotting, an effect due to its potentiating interaction with the natural inhibitor of thrombin, antithrombin III. These properties have led to widespread use of heparin as an anticoagulant although scant attention has been paid to other biological activities of this GAG.
This situation has changed in recent years. In fact is has long been
recognised that heparin has a wide range of biological effects
Relevant Article
-
Heparin attenuates TNF-
induced inflammatory response through a CD11b dependent mechanism
- A Salas, M Sans, A Soriano, J C Reverter, D C Anderson, J M Piqué, and J Panés
Gut 2000 47: 88-96.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
-
Christopherson, K. W. II, Campbell, J. J., Travers, J. B., Hromas, R. A.
(2002). Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration. J. Pharmacol. Exp. Ther.
302: 290-295
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
